Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

NCT01192165 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Trametinib (GSK1120212)
DRUG: Docetaxel
DRUG: Erlotinib
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: nab-Paclitaxel
DRUG: Cisplatin

Sponsor

GlaxoSmithKline